Actively Recruiting
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-11-17
120
Participants Needed
1
Research Sites
168 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
CONDITIONS
Official Title
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understands the study and is willing to sign consent with good compliance
- Aged between 18 and 75 years
- ECOG performance status score of 0 or 1
- Life expectancy greater than 3 months
- At least one measurable lesion based on RECIST v1.1
- Adequate organ function
You will not qualify if you...
- Toxicity from prior anti-tumor treatment not recovered to Grade �3C= 1 or specified level
- Presence of central nervous system metastases
- Gastrointestinal diseases affecting drug administration or absorption
- Major surgery within 28 days before first dose or planned during study
- Serious pulmonary diseases
- Active or recent tuberculosis within 48 weeks prior to screening
- Active or persistent gastrointestinal bleeding within 6 months prior to screening
- History of allogeneic bone marrow or solid organ transplantation
- History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening
- Uncontrolled pleural, pericardial effusion, or ascites needing intervention
- Positive HIV, active chronic hepatitis B, or active hepatitis C infection
- Known allergy to any component of the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Affiliated Cancer Hospital
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
R
Rongfu Mao
CONTACT
J
Jizhao Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here